MedTrace Logo

Mechanism of Action Trial of ColoAd1

NCT02053220 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-03-12

No results posted yet for this study

Summary

To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following ColoAd1 administration by intravenous infusion.

Conditions

  • Resectable Colon Cancer
  • Resectable Non-small Cell Lung Cancer
  • Resectable Bladder Cancer
  • Resectable Renal Cell Carcinoma

Interventions

BIOLOGICAL

Colo-Ad1

Oncolytic virus

Sponsors & Collaborators

  • Akamis Bio

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-04-30
Completion
2016-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02053220 on ClinicalTrials.gov